- 1.
CDR submission: duobrii (halobetasol propionate (0.01%) and tazarotene (0.045%) lotion, once daily [CONFIDENTIAL sponsor’s submission]. Laval (QC): Bausch Health, Canada Inc.; 2020
Feb
3.
- 2.
Blauvelt
A, Ehst
B. Pathophysiology of psoriasis.
UpToDate. Waltham (MA): UpToDate; 2019:
www.uptodate.com. Accessed 2019 Oct 15.
- 3.
Papp
K, Gulliver
W, Lynde
C, Poulin
Y, Ashkenas
J, Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview.
J Cutan Med Surg. 2011;15(4):210–219. [
PubMed: 21781627]
- 4.
- 5.
- 6.
Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009.
J Cutan Med Surg. 2016;20(5):375–431. [
PMC free article: PMC5014087] [
PubMed: 27421294]
- 7.
Menter
A, Korman
NJ, Elmets
CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
J Am Acad Dermatol. 2009;60(4):643–659. [
PubMed: 19217694]
- 8.
- 9.
Duobrii (halobetasol propionate and tazarotene lotion 0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) [product monograph]. Laval (QC): Bausch Health, Canada Inc.; 2020
Jun
8.
- 10.
Clinical Study Report: V01-118A-301. A phase 3, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of IDP-118 in the treatment of plaque psoriasis [CONFIDENTIAL internal sponsor’s report]. Petaluma (CA): Valeant Pharmaceuticals North America LLC; 2017
Feb
28.
- 11.
Clinical Study Report: V01-118A-302. A phase 3, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of IDP-118 in the treatment of plaque psoriasisTitle of report [CONFIDENTIAL internal sponsor’s report]. Petaluma (CA): Valeant Pharmaceuticals North America LCC; 2017
Feb
28.
- 12.
Weisman
S, Pollack
CR, Gottschalk
RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.
J Dermatolog Treat. 2003;14(3):158–165. [
PubMed: 14522626]
- 13.
Elmets
CA, Leonardi
CL, Davis
DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
J Am Acad Dermatol. 2019;80(4):1073–1113. [
PubMed: 30772097]
- 14.
Menter
A, Gelfand
JM, Connor
C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
J Am Acad Dermatol. 2020;82(6):1445–1486. [
PubMed: 32119894]
- 15.
- 16.
Bhole
VM, Choi
HK, Burns
LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population.
Rheumatology (Oxford). 2012;51(3):552–556. [
PubMed: 22120603]
- 17.
Dowlatshahi
EA, Wakkee
M, Arends
LR, Nijsten
T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.
J Invest Dermatol. 2014;134(6):1542–1551. [
PubMed: 24284419]
- 18.
Eder
L, Chandran
V, Shen
H, et al. Incidence of arthritis in a prospective cohort of psoriasis patients.
Arthritis Care Res (Hoboken). 2011;63(4):619–622. [
PubMed: 21452273]
- 19.
Kimball
AB, Guerin
A, Latremouille-Viau
D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.
Am J Med. 2010;123(4):350–357. [
PubMed: 20362755]
- 20.
Li
W, Han
J, Hu
FB, Curhan
GC, Qureshi
AA. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study.
J Invest Dermatol. 2012;132(2):291–298. [
PMC free article: PMC3743422] [
PubMed: 21993559]
- 21.
Samarasekera
EJ, Neilson
JM, Warren
RB, Parnham
J, Smith
CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis.
J Invest Dermatol. 2013;133(10):2340–2346. [
PubMed: 23528816]
- 22.
Wan
J, Wang
S, Haynes
K, Denburg
MR, Shin
DB, Gelfand
JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study.
BMJ. 2013;347:f5961. [
PMC free article: PMC3805477] [
PubMed: 24129480]
- 23.
- 24.
Kragballe
K. Topical corticosteroids: mechanisms of action.
Acta Derm Venereol Suppl (Stockh). 1989;151:7–10; discussion 47–52. [
PubMed: 2533778]
- 25.
Silkis (calcitriol): 3 μg/g ointment [product monograph]. Thornhill (ON): Galderma Canada Inc.; 2017
Oct
17.
- 26.
Dovonex (calcipotriol): cream and ointment, 50 mcg/g scalp solution, 50 mcg/mL [product monograph]. Thornhill (ON): LEO Pharma Inc.; 2007
Oct
9.
- 27.
Dovobet gel (calcipotriol and betamethasone dipropionate gel): 50 mcg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate) gel [product monograph]. Thornhill (ON): LEO Pharma Inc.; 2020
Feb
25.
- 28.
Dovobet (calcipotriol and betamethasone dipropionate): ointment, 50 mcg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate) [product monograph]. Thornhill (ON): LEO Pharma Inc.; 2016
Apr
4.
- 29.
Enstilar (calcipotriol and betamethasone dipropionate aerosol foam): 50 mcg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate) [product monograph]. Thornhill (ON): LEO Pharma Inc.; 2020
Jan
22.
- 30.
Duobrii (halobetasol propionate and tazarotene lotion): 0.01% w/w halobetasol propionate and 0.045% w/w tazarotene [product monograph]. Laval (QC): Bausch Health, Canada Inc.; 2020
Mar
19. Accessed 2020 May 8.
- 31.
McGowan
J, Sampson
M, Salzwedel
DM, Cogo
E, Foerster
V, Lefebvre
C. PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement.
J Clin Epidemiol. 2016;75:40–46. [
PubMed: 27005575]
- 32.
- 33.
Finlay
AY, Khan
GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use.
Clin Exp Dermatol. 1994;19(3):210–216. [
PubMed: 8033378]
- 34.
Shikiar
R, Willian
MK, Okun
MM, Thompson
CS, Revicki
DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
Health Qual Life Outcomes. 2006;4:71. [
PMC free article: PMC1615869] [
PubMed: 17005043]
- 35.
Long
CC. Finlay AY AR. The rule of hand: 4 areas = 2 FTU = 1 g.
Arch Dermatol. 1992;128(8):1129–1130. [
PubMed: 1497374]
- 36.
Merola
JF, Amato
DA, See
K, et al. Evaluation of sPGA x BSA as an Outcome Measure and Treatment Target for Clinical Practice.
J Invest Dermatol. 2018;138(9):1955–1961. [
PubMed: 29577919]
- 37.
Smith
CH, Jabbar-Lopez
ZK, Yiu
ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
Br J Dermatol. 2017;177:628–636. [
PubMed: 28513835]
- 38.
Basra
MK, Fenech
R, Gatt
RM, Salek
MS, Finlay
AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results.
Br J Dermatol. 2008;159(5):997–1035. [
PubMed: 18795920]
- 39.
Efficacy of topical therapies for plaque psoriasis: a systematic literature review and network meta-analysis In: CDR submission: duobrii (halobetasol propionate (0.01%) and tazarotene (0.045%) lotion, once daily [CONFIDENTIAL sponsor’s submission]. Laval (QC): Bausch Health, Canada Inc.; 2020
Feb
3.
- 40.
Clinical Study Report: V01-118A-303. A phase 3, multicenter, open label study to evaluate the long term safety of IDP-118 lotion in the treatment of plaque psoriasis [CONFIDENTIAL internal sponsor’s report]. Petaluma (CA): Valeant Pharmaceuticals North America LCC; 2017
Jul
10.
- 41.
Clinical Study Report: V01-118A-201
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis [CONFIDENTIAL internal sponsor’s report]. 2015. [
PubMed: 28301614]
- 42.
Center for Drug Evaluation and Research. Multi-discipline review. Duobrii (halobetasol and tazarotene lotion, 0.01%/0.045%). Company: Bausch Health, Canada Inc. Application No.:209354. Approval date: 04/15/2019. Rockville (MD): U. S. Food and Drug Administration (FDA); 2019
Apr
24: URL. Accessed 2020 May 27.
- 43.
Bausch Health Canada response to February 11 2020 request for additional information regarding duobrii CDR review: CSR for the pooled analysis. [CONFIDENTIAL additional sponsor’s information]. Laval (QC): Bausch Health, Canada Inc.; 2020
Feb
19.
- 44.
Landis
JR, Koch
GG. The measurement of observer agreement for categorical data.
Biometrics. 1977;33(1):159–174. [
PubMed: 843571]
- 45.
Reeve
BB, Wyrwich
KW, Wu
AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research.
Qual Life Res. 2013;22(8):1889–1905. [
PubMed: 23288613]
- 46.
- 47.
Melilli
L, Shikiar
R, Thompson
C. Minimal clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with adalimumab. Journal of American Academy of Dermatology. 2006;54(AB221(P2894)).
- 48.
Ali
FM, Salek
MS, Finlay
AY, Piguet
V. Validation of the electronic PASI application: establishing measurement equivalence.
J Am Acad Dermatol. 2019;19:19. [
PubMed: 31228524]
- 49.
Reolid
A, Servitje
O, Ginarte
M, et al. Validation of an optical pencil method to estimate the affected body surface area in psoriasis.
Actas Dermo Sifiliograficas. 2019;28:28. [
PubMed: 31472926]
- 50.
Chandran
V, Gottlieb
A, Cook
RJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis.
Arthritis Rheum. 2009;61(9):1235–1242. [
PubMed: 19714610]
- 51.
Puzenat
E, Bronsard
V, Prey
S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:10–16. [
PubMed: 20443995]
- 52.
Bozek
A, Reich
A. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Adv. 2017;26(5):851–856. [
PubMed: 29068583]
- 53.
Lewis
V, Finlay
AY. 10 years experience of the Dermatology Life Quality Index (DLQI).
J Investig Dermatol Symp Proc. 2004;9(2):169–180. [
PubMed: 15083785]
- 54.
Shikiar
R, Bresnahan
BW, Stone
SP, Thompson
C, Koo
J, Revicki
DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.
Health Qual Life Outcomes. 2003;1:53. [
PMC free article: PMC269993] [
PubMed: 14613569]
- 55.
Mazzotti
E, Picardi
A, Sampogna
F, Sera
F, Pasquini
P, Abeni
D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.
Br J Dermatol. 2003;149(2):318–322. [
PubMed: 12932238]
- 56.
Both
H, Essink-Bot
ML, Busschbach
J, Nijsten
T. Critical review of generic and dermatology-specific health-related quality of life instruments.
J Invest Dermatol. 2007;127(12):2726–2739. [
PubMed: 17989733]
- 57.
- 58.
Langley
RG, Ellis
CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment.
J Am Acad Dermatol. 2004;51(4):563–569. [
PubMed: 15389191]
- 59.
Robinson
A, Kardos
M, Kimball
AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
J Am Acad Dermatol. 2012;66(3):369–375. [
PubMed: 22041254]
- 60.
Langley
RG, Feldman
SR, Nyirady
J, van de Kerkhof
P, Papavassilis
C. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
J Dermatolog Treat. 2015;26(1):23–31. [
PubMed: 24354461]
- 61.
Callis Duffin
K, Bushmakin
AG, Cappelleri
JC, Mallbris
L, Mamolo
C. A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.
BMC Dermatol. 2019;19(1):8. [
PMC free article: PMC6555979] [
PubMed: 31174539]
- 62.
Simpson
MJ, Chow
C, Morgenstern
H, Luger
TA, Ellis
CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician’s Global Assessment, Psoriasis Area and Severity Index and Static Physician’s Global Assessment.
J Eur Acad Dermatol Venereol. 2015;29(7):1415–1420. [
PubMed: 25917214]
- 63.
Cappelleri
JC, Bushmakin
AG, Harness
J, Mamolo
C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.
Qual Life Res. 2013;22(9):2489–2499. [
PubMed: 23475691]
- 64.
Berth-Jones
J, Grotzinger
K, Rainville
C, et al. A Study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment.
Br J Dermatol. 2006;155(4):707–713. [
PubMed: 16965419]
- 65.
Bozek
A, Reich
A. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2017;26(5):851–856. [
PubMed: 29068583]
- 66.
Spuls
PI, Lecluse
LL, Poulsen
ML, Bos
JD, Stern
RS, Nijsten
T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
J Invest Dermatol. 2010;130(4):933–943. [
PubMed: 20043014]
- 67.
Fleischer
AB, Jr., Feldman
SR, Dekle
CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial.
J Dermatol. 1999;26(4):210–215. [
PubMed: 10343464]
- 68.
Rhodes
J, Clay
C, Phillips
M. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta-analysis.
Br J Dermatol. 2013;169(1):76–84. [
PubMed: 23448271]
